We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+31.25%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.67B
AUM Growth
+$753M
Cap. Flow
-$209M
Cap. Flow %
-7.82%
Top 10 Hldgs %
54.38%
Holding
380
New
93
Increased
88
Reduced
106
Closed
73

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$10.1M
2
CYTR
CytRx Corp
CYTR
+$5.67M
3
CELG
Celgene Corp
CELG
+$4.08M
4
UTHR icon
United Therapeutics
UTHR
+$3.38M
5
DVAX
Dynavax Technologies
DVAX
+$3.33M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$7.47M
2
ABT icon
Abbott
ABT
+$6.5M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$4.84M
4
NVIV
InVivo Therapeutics Holdings Corp
NVIV
+$3.87M
5
AMGN icon
Amgen
AMGN
+$3.54M

Sector Composition

Rank Sector Weight
1 Healthcare 9.24%
2 Consumer Staples 0.04%
3 Technology 0.03%
4 Industrials 0.01%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMUC
201
DELISTED
ImmunoCellular Therapeutics, Ltd.
IMUC
$756K 0.03%
160,131
+48,828
+44% +$314K
XTLB
202
XTL Biopharmaceuticals
XTLB
$7.27M
$714K 0.03%
37,564
-12,495
-25% -$271K
GNVC
203
DELISTED
GenVec, Inc.
GNVC
$696K 0.03%
151,038
-11,506
-7% -$66.4K
PTLA
204
CALL
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$681K 0.03%
+300
New +$7.04K
ABUS icon
205
CALL
Arbutus Biopharma
ABUS
$847M
$670K 0.03%
1,949
+1,280
+191% +$5K
FOMX
206
CALL
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$670K 0.03%
+724
New +$6.05K
SCON
207
DELISTED
Superconductor Technologies Inc.
SCON
$669K 0.03%
2,505
+1,371
+121% +$366K
ANTH
208
CALL
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$668K 0.03%
265
+55
+26% +$1.39K
MRTX
209
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$659K 0.02%
99,735
-7,500
-7% -$39.9K
EYPT icon
210
EyePoint Inc
EYPT
$999M
$587K 0.02%
19,510
-6,270
-24% -$227K
TENX icon
211
CALL
Tenax Therapeutics
TENX
$393M
– –
0
– –
ACUR
212
DELISTED
Acura Pharmaceuticals
ACUR
$565K 0.02%
352,835
-165,609
-32% -$293K
BPMC
213
PUT
DELISTED
Blueprint Medicines
BPMC
$564K 0.02%
+190
New +$4.72K
PCRX icon
214
PUT
Pacira BioSciences
PCRX
$1.04B
$544K 0.02%
+159
New +$6.23K
ASMB icon
215
Assembly Biosciences
ASMB
$498M
$542K 0.02%
6,267
-1,263
-17% -$97.6K
PARN
216
DELISTED
Parnell Pharmaceuticals Holdings Ltd
PARN
$532K 0.02%
369,700
-19,700
-5% -$30.5K
LUMO
217
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$519K 0.02%
3,840
+700
+22% +$69.5K
NUWE icon
218
Nuwellis
NUWE
$174K
– –
0
– –
RNVA
219
DELISTED
Rennova Health, Inc.
RNVA
$516K 0.02%
+6,055
New +$795K
SSKN
220
DELISTED
Strata Skin Sciences
SSKN
$510K 0.02%
20,016
-394
-2% -$12.5K
MDCO
221
DELISTED
Medicines Co
MDCO
$510K 0.02%
13,508
+6,508
+93% +$245K
TSRO
222
PUT
DELISTED
TESARO, Inc.
TSRO
$501K 0.02%
+50
New +$4.67K
ELDN icon
223
Eledon Pharmaceuticals
ELDN
$255M
$492K 0.02%
1,985
-2,640
-57% -$966K
BDSI
224
CALL
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$478K 0.02%
1,770
+144
+9% +$366
CYH icon
225
PUT
Community Health Systems
CYH
$382M
$477K 0.02%
+413
New +$4.76K
7 8
9
10 11

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q3 2016 Portfolio in Review

As of Q3 2016, Sabby Management held 380 positions worth $2.67B, up 39% from $1.92B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Sabby Management withdrew a net $209M in Q3 2016, closing 73 positions and reducing 106 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $4.84M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 9.2% of assets, down from 13% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, Sabby Management opened a new position in Bristol-Myers Squibb worth $8.46M.

  • Sabby Management's largest Q3 2016 buy was Bristol-Myers Squibb: 156,887 shares worth $8.46M.
  • Sabby Management added most to Dynavax Technologies in Q3 2016, an estimated $3.33M increase.
  • Sabby Management's biggest Q3 2016 reduction was Sarepta Therapeutics, cutting an estimated $7.47M.
  • Sabby Management fully exited Global Blood Therapeutics, Inc. in Q3 2016, selling an estimated $4.84M.
  • Sabby Management's ten largest holdings make up 54% of its $2.67B portfolio in Q3 2016.
  • Sabby Management opened 93 new positions and closed 73 in Q3 2016.
  • Sabby Management's portfolio value rose 39% quarter-over-quarter to $2.67B.

Based on Sabby Management's 13F filing for Q3 2016, filed 14 Nov 2016.